Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:810-815, doi:10.1016/j.jacc.2007.09.065
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Current Clinical Collection-Atrial Fibrillation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, M. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fang, M. C.
Related Collections
Right arrowRelated Articles

FOCUS ISSUE: ATRIAL FIBRILLATION: CLINICAL RESEARCH: ATRIAL FIBRILLATION AND EMBOLISM

Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation

Margaret C. Fang, MD, MPH*,*, Alan S. Go, MD*,{dagger}, Yuchiao Chang, PhD{ddagger}, Leila Borowsky, MPH{ddagger}, Niela K. Pomernacki, RD{dagger}, Daniel E. Singer, MD{ddagger} for the ATRIA Study Group

* Department of Medicine, University of California at San Francisco, San Francisco, California
{dagger} Division of Research, Kaiser Permanente of Northern California, Oakland, California
{ddagger} Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, Massachusetts.

Manuscript received July 2, 2007; revised manuscript received September 11, 2007, accepted September 17, 2007.

* Reprint requests and correspondence: Dr. Margaret C. Fang, 503 Parnassus Avenue, Box 0131, San Francisco, California 94143. (Email: mfang{at}medicine.ucsf.edu).

Objectives: We assessed 5 risk stratification schemes for their ability to predict atrial fibrillation (AF)–related thromboembolism in a large community-based cohort.

Background: Risk schemes can help target anticoagulant therapy for patients at highest risk for AF–related thromboembolism. We tested the predictive ability of 5 risk schemes: the Atrial Fibrillation Investigators, Stroke Prevention in Atrial Fibrillation, CHADS2 (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and the 7th American College of Chest Physicians Guidelines.

Methods: We followed a cohort of 13,559 adults with AF for a median of 6.0 years. Among non-warfarin users, we identified incident thromboembolism (ischemic stroke or peripheral embolism) and risk factors from clinical databases. Each scheme was divided into low, intermediate, and high predicted risk categories and applied to the cohort. Annualized thromboembolism rates and c-statistics (to assess discrimination) were calculated for each risk scheme.

Results: We identified 685 validated thromboembolic events that occurred during 32,721 person-years off warfarin therapy. The risk schemes had only fair discriminating ability, with c-statistics ranging from 0.56 to 0.62. The proportion of patients assigned to individual risk categories varied widely across the schemes. The proportion categorized as low risk ranged from 11.7% to 37.1% across schemes, and the proportion considered high risk ranged from 16.4% to 80.4%.

Conclusions: Current risk schemes have comparable, but only limited, overall ability to predict thromboembolism in persons with AF. Recommendations for antithrombotic therapy may vary widely depending on which scheme is applied for individual patients. Better risk stratification is crucially needed to improve selection of AF patients for anticoagulant therapy.

Abbreviations and Acronyms
  ACCP = American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy
  AF = atrial fibrillation
  AFI = Atrial Fibrillation Investigators
  CHADS2 = Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, and prior Stroke or transient ischemic attack
  CI = confidence interval
  ICD-9-CM = International Classification of Diseases-Ninth Revision-Clinical Modification


Related Articles

Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation
William S. Weintraub
J. Am. Coll. Cardiol. 2008 51: 816-817. [Full Text] [PDF]

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A23-A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
CirculationHome page
A. S. Go, N. Udaltsova, N. K. Pomernacki, M. C. Fang, Y. Chang, L. Borowsky, and D. E. Singer
Response to Letter Regarding Article, "Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study"
Circulation, November 3, 2009; 120(18): e154 - e154.
[Full Text] [PDF]


Home page
HeartHome page
N Allou, P Piednoir, C Berroeta, S Provenchere, H Ibrahim, G Baron, P Montravers, B Iung, I Philip, and N Ajzenberg
Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin
Heart, October 15, 2009; 95(20): 1694 - 1700.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. M. Sood, P. Komenda, A. R. Sood, C. Rigatto, and J. Bueti
The Intersection of Risk and Benefit: Is Warfarin Anticoagulation Suitable for Atrial Fibrillation in Patients on Hemodialysis?
Chest, October 1, 2009; 136(4): 1128 - 1133.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Ann Intern Med, September 1, 2009; 151(5): 297 - 305.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc Qual OutcomesHome page
D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go
Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study
Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al.
Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'
Europace, July 1, 2009; 11(7): 860 - 885.
[Full Text] [PDF]


Home page
StrokeHome page
R. G. Hart and L. A. Pearce
Current Status of Stroke Risk Stratification in Patients With Atrial Fibrillation
Stroke, July 1, 2009; 40(7): 2607 - 2610.
[Full Text] [PDF]


Home page
NEJMHome page
A. S. Go
The ACTIVE Pursuit of Stroke Prevention in Patients with Atrial Fibrillation
N. Engl. J. Med., May 14, 2009; 360(20): 2127 - 2129.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. H Kim, D. Klingman, J. Lin, P. Pathak, and D. S Battleman
Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation
Ann. Pharmacother., May 1, 2009; 43(5): 840 - 848.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. S. Go, M. C. Fang, N. Udaltsova, Y. Chang, N. K. Pomernacki, L. Borowsky, D. E. Singer, and for the ATRIA Study Investigators
Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Circulation, March 17, 2009; 119(10): 1363 - 1369.
[Abstract] [Full Text] [PDF]


Home page
Age AgeingHome page
V. Perera, B. V. Bajorek, S. Matthews, and S. N. Hilmer
The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation
Age Ageing, March 1, 2009; 38(2): 156 - 162.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398.
[Full Text] [PDF]


Home page
HeartHome page
R. Nieuwlaat and S. J Connolly
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes
Heart, January 15, 2009; 95(2): 95 - 97.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
K. Fatema, K. R. Bailey, G. W. Petty, I. Meissner, M. Osranek, A. A. Alsaileek, B. K. Khandheria, T. S. Tsang, and J. B. Seward
Increased Left Atrial Volume Index: Potent Biomarker for First-Ever Ischemic Stroke
Mayo Clin. Proc., October 1, 2008; 83(10): 1107 - 1114.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin
Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Stroke Risk in Atrial Fibrillation Working Group
Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke, June 1, 2008; 39(6): 1901 - 1910.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. S. Weintraub
Predicting Thromboembolism and Selecting Patients for Anticoagulant Therapy in Atrial Fibrillation
J. Am. Coll. Cardiol., February 26, 2008; 51(8): 816 - 817.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement